mTOR inhibition triggers mitochondrial fragmentation in cardiomyocytes through proteosome-dependent prohibitin degradation and OPA-1 cleavage

By sjmartinez • June 1, 2025

Verdejo HE, Parra V, Del Campo A, Vasquez-Trincado C, Gatica D, Lopez-Crisosto C, Kuzmicic J, Venegas-Zamora L, Zuñiga-Cuevas U, Troncoso MF, Troncoso R, Rothermel BA, Chiong M, Abel ED, Lavandero S. mTOR inhibition triggers mitochondrial fragmentation in cardiomyocytes through proteosome-dependent prohibitin degradation and OPA-1 cleavage. Cell Commun Signal. 2025 May 31;23(1):256. doi: 10.1186/s12964-025-02240-w. PMID: 40450326.

Tags: AMPK, Endocrinology, Mitochondrial fusion, mTOR, Oma1, OPA-1, Prohibitin, Publications, Rapamycin

Efficacy and safety of relacorilant for the treatment of patients with Cushing’s syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

Pivonello R, Arnaldi G, Auchus RJ, Badiu C, Busch RS, Cannavò S, Dischinger U, Dobri GA, Donegan DM, Elenkova A, Fazeli PK, Feelders RA, Garcia-Centeno[...]

Stephanie Smooke Praw, MD Appointed Interim Chief of the UCLA Division of Endocrinology

The UCLA Department of Medicine is delighted to announce that Stephanie Smooke Praw, MD has been appointed interim chief of the UCLA Division of Endocrinology, expanding upon her[...]

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions

Pahulu I, Calumpit M, Tominez P, Shih JJ, Ebrahimi S, Deville NV, Samoa R, Moin T, Sedrak MS, Valle LF, Steinberg M, Kishan AU, Ganz[...]